{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:28:32Z","timestamp":1793831312037,"version":"4.6.1"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,12,30]],"date-time":"2019-12-30T00:00:00Z","timestamp":1577664000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,12,30]],"date-time":"2019-12-30T00:00:00Z","timestamp":1577664000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Hypertrophic cardiomyopathy (HCM) is one of the most common hereditary heart diseases and is associated with a high risk of sudden cardiac death. HCM is characterized by pronounced hypertrophy of cardiomyocytes, fiber disarray and development of fibrosis and can be divided into a non-obstructive (HNCM) and obstructive form (HOCM) therefore requiring personalized therapeutic therapies. In the present study, we investigated the expression patterns of several\u00a0circulating circular RNAs (circRNAs) as potential biomarkers in patients with HCM. We included 64 patients with HCM and 53 healthy controls to the study and quantitatively measured the expression of a set of circRNAs already known to be associated with cardiac diseases (circDNAJC6) and\/or being highly abundant in blood (circTMEM56 and circMBOAT2). Abundancy of circRNAs was then correlated to relevant clinical parameters. Serum expression levels of circRNAs DNAJC6, TMEM56 and MBOAT2 were downregulated in patients with HCM. The inverse association between circRNA levels and HCM remained unchanged even after adjusting for confounding factors. All circRNAs, evaluated separately or in combination, showed a robust discrimination capacity when comparing control subjects with HCM, HNCM or HOCM patients (AUC from 0.722 to 0.949). Two circRNAs, circTMEM56 and circDNAJC6, significantly negatively correlated with echocardiographic parameters for HOCM. Collectively, circulating circRNAs DNAJC6, TMEM56 and MBOAT2 can distinguish between healthy and HCM patients. In addition, circTMEM56 and circDNAJC6 could serve as indicators of disease severity in patients with HOCM. Thus, circRNAs emerge as novel biomarkers for HCM facilitating the clinical decision making in a personalized manner.<\/jats:p>","DOI":"10.1038\/s41598-019-56617-2","type":"journal-article","created":{"date-parts":[[2019,12,30]],"date-time":"2019-12-30T06:02:44Z","timestamp":1577685764000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":70,"title":["Serum circular RNAs act as blood-based biomarkers for hypertrophic obstructive cardiomyopathy"],"prefix":"10.1038","volume":"9","author":[{"given":"Kristina","family":"Sonnenschein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana Luisa","family":"Wilczek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"de Gonzalo-Calvo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelika","family":"Pfanne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anselm Arthur","family":"Derda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carolin","family":"Zwadlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Udo","family":"Bavendiek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann","family":"Bauersachs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Fiedler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Thum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,12,30]]},"reference":[{"key":"56617_CR1","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1056\/NEJMra1710575","volume":"379","author":"BJ Maron","year":"2018","unstructured":"Maron, B. J. Clinical Course and Management of Hypertrophic Cardiomyopathy. N Engl J Med. 379, 655\u2013668 (2018).","journal-title":"N Engl J Med."},{"key":"56617_CR2","doi-asserted-by":"publisher","first-page":"376","DOI":"10.1016\/j.jchf.2018.03.004","volume":"6","author":"BJ Maron","year":"2018","unstructured":"Maron, B. J., Rowin, E. J. & Maron, M. S. Global Burden of Hypertrophic Cardiomyopathy. JACC Heart Fail. 6, 376\u2013378 (2018).","journal-title":"JACC Heart Fail."},{"key":"56617_CR3","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/j.jacc.2015.01.019","volume":"65","author":"C Semsarian","year":"2015","unstructured":"Semsarian, C., Ingles, J., Maron, M. S. & Maron, B. J. New perspectives on the prevalence of hypertrophic cardiomyopathy. J Am Coll Cardiol. 65, 1249\u20131254 (2015).","journal-title":"J Am Coll Cardiol."},{"issue":"35","key":"56617_CR4","first-page":"2733","volume":"2014","author":"PM Elliott","year":"2014","unstructured":"Authors\/Task Force members, Elliott, P. M. et al. ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J. 2014(35), 2733\u20132779 (2014).","journal-title":"Eur Heart J."},{"key":"56617_CR5","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1093\/eurheartj\/ehy234","volume":"40","author":"D de Gonzalo-Calvo","year":"2019","unstructured":"de Gonzalo-Calvo, D. et al. Circulating non-coding RNAs in biomarker-guided cardiovascular therapy: a novel tool for personalized medicine? Eur Heart J. 40, 1643\u20131650 (2019).","journal-title":"Eur Heart J."},{"key":"56617_CR6","doi-asserted-by":"publisher","first-page":"H707","DOI":"10.1152\/ajpheart.00194.2016","volume":"311","author":"J Kitow","year":"2016","unstructured":"Kitow, J. et al. Mitochondrial long noncoding RNAs as blood based biomarkers for cardiac remodeling in patients with hypertrophic cardiomyopathy. Am J Physiol Heart Circ Physiol. 311, H707\u201312 (2016).","journal-title":"Am J Physiol Heart Circ Physiol."},{"key":"56617_CR7","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.ijcard.2015.05.185","volume":"196","author":"AA Derda","year":"2015","unstructured":"Derda, A. A. et al. Blood-based microRNA signatures differentiate various forms of cardiac hypertrophy. Int J Cardiol. 196, 115\u2013122 (2015).","journal-title":"Int J Cardiol."},{"key":"56617_CR8","doi-asserted-by":"publisher","first-page":"2266","DOI":"10.1111\/jcmm.12380","volume":"18","author":"L Song","year":"2014","unstructured":"Song, L. et al. MiR-451 is decreased in hypertrophic cardiomyopathy and regulates autophagy by targeting TSC1. J Cell Mol Med. 18, 2266\u20132274 (2014).","journal-title":"J Cell Mol Med."},{"key":"56617_CR9","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.jacc.2013.09.041","volume":"63","author":"R Roncarati","year":"2014","unstructured":"Roncarati, R. et al. Circulating miR-29a, among other up-regulated microRNAs, is the only biomarker for both hypertrophy and fibrosis in patients with hypertrophic cardiomyopathy. J Am Coll Cardiol. 63, 920\u2013927 (2014).","journal-title":"J Am Coll Cardiol."},{"key":"56617_CR10","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1002\/jcp.27384","volume":"234","author":"MA Altesha","year":"2019","unstructured":"Altesha, M. A., Ni, T., Khan, A., Liu, K. & Zheng, X. Circular RNA in cardiovascular disease. J Cell Physiol. 234, 5588\u20135600 (2019).","journal-title":"J Cell Physiol."},{"key":"56617_CR11","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1002\/cam4.1514","volume":"7","author":"D Hang","year":"2018","unstructured":"Hang, D. et al. A novel plasma circular RNA circFARSA is a potential biomarker for non-small cell lung cancer. Cancer Med. 7, 2783\u20132791 (2018).","journal-title":"Cancer Med."},{"key":"56617_CR12","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.1093\/hmg\/ddx243","volume":"26","author":"L Iparraguirre","year":"2017","unstructured":"Iparraguirre, L. et al. Circular RNA profiling reveals that circular RNAs from ANXA2 can be used as new biomarkers for multiple sclerosis. Hum Mol Genet. 26, 3564\u20133572 (2017).","journal-title":"Hum Mol Genet."},{"key":"56617_CR13","doi-asserted-by":"publisher","first-page":"e0141214","DOI":"10.1371\/journal.pone.0141214","volume":"10","author":"S Memczak","year":"2015","unstructured":"Memczak, S., Papavasileiou, P., Peters, O. & Rajewsky, N. Identification and Characterization of Circular RNAs As a New Class of Putative Biomarkers in Human Blood. PLoS One. 10, e0141214 (2015).","journal-title":"PLoS One."},{"key":"56617_CR14","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1261\/rna.035667.112","volume":"19","author":"WR Jeck","year":"2013","unstructured":"Jeck, W. R. et al. Circular RNAs are abundant, conserved, and associated with ALU repeats. RNA. 19, 141\u2013157 (2013).","journal-title":"RNA."},{"key":"56617_CR15","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/j.yjmcc.2016.07.007","volume":"98","author":"S Werfel","year":"2016","unstructured":"Werfel, S. et al. Characterization of circular RNAs in human, mouse and rat hearts. J Mol Cell Cardiol. 98, 103\u2013107 (2016).","journal-title":"J Mol Cell Cardiol."},{"key":"56617_CR16","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1038\/nature11993","volume":"495","author":"TB Hansen","year":"2013","unstructured":"Hansen, T. B. et al. Natural RNA circles function as efficient microRNA sponges. Nature. 495, 384\u2013388 (2013).","journal-title":"Nature."},{"key":"56617_CR17","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1038\/nature11928","volume":"495","author":"S Memczak","year":"2013","unstructured":"Memczak, S. et al. Circular RNAs are a large class of animal RNAs with regulatory potency. Nature. 495, 333\u2013338 (2013).","journal-title":"Nature."},{"key":"56617_CR18","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1038\/nsmb.2959","volume":"22","author":"Z Li","year":"2015","unstructured":"Li, Z. et al. Exon-intron circular RNAs regulate transcription in the nucleus. Nat Struct Mol Biol. 22, 256\u2013264 (2015).","journal-title":"Nat Struct Mol Biol."},{"key":"56617_CR19","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1161\/CIRCRESAHA.116.309568","volume":"119","author":"MA Khan","year":"2016","unstructured":"Khan, M. A. et al. RBM20 Regulates Circular RNA Production From the Titin Gene. Circ Res. 119, 996\u20131003 (2016).","journal-title":"Circ Res."},{"key":"56617_CR20","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1161\/CIRCRESAHA.117.311335","volume":"122","author":"SK Gupta","year":"2018","unstructured":"Gupta, S. K. et al. Quaking Inhibits Doxorubicin-Mediated Cardiotoxicity Through Regulation of Cardiac Circular RNA Expression. Circ Res. 122, 246\u2013254 (2018).","journal-title":"Circ Res."},{"key":"56617_CR21","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1038\/cr.2015.82","volume":"25","author":"Y Li","year":"2015","unstructured":"Li, Y. et al. Circular RNA is enriched and stable in exosomes: a promising biomarker for cancer diagnosis. Cell Res. 25, 981\u2013984 (2015).","journal-title":"Cell Res."},{"key":"56617_CR22","doi-asserted-by":"publisher","first-page":"e0151753","DOI":"10.1371\/journal.pone.0151753","volume":"11","author":"HH Geng","year":"2016","unstructured":"Geng, H. H. et al. The Circular RNA Cdr1as Promotes Myocardial Infarction by Mediating the Regulation of miR-7a on Its Target Genes Expression. PLoS One. 11, e0151753 (2016).","journal-title":"PLoS One."},{"key":"56617_CR23","doi-asserted-by":"publisher","first-page":"1247","DOI":"10.1016\/j.jacc.2016.06.040","volume":"68","author":"M Vausort","year":"2016","unstructured":"Vausort, M. et al. Myocardial Infarction-Associated Circular RNA Predicting Left Ventricular Dysfunction. J Am Coll Cardiol. 68, 1247\u20131248 (2016).","journal-title":"J Am Coll Cardiol."},{"key":"56617_CR24","first-page":"33","volume":"17","author":"A Salgado-Somoza","year":"2017","unstructured":"Salgado-Somoza, A., Zhang, L., Vausort, M. & Devaux, Y. The circular RNA MICRA for risk stratification after myocardial infarction. Int J Cardiol Heart Vasc. 17, 33\u201336 (2017).","journal-title":"Int J Cardiol Heart Vasc."},{"key":"56617_CR25","doi-asserted-by":"publisher","first-page":"1402","DOI":"10.1093\/eurheartj\/ehx501.P440","volume":"38","author":"WW Du","year":"2017","unstructured":"Du, W. W. et al. Foxo3 circular RNA promotes cardiac senescence by modulating multiple factors associated with stress and senescence responses. Eur Heart J. 38, 1402\u20131412 (2017).","journal-title":"Eur Heart J."},{"key":"56617_CR26","doi-asserted-by":"publisher","DOI":"10.1038\/srep40342","volume":"7","author":"CM Tang","year":"2017","unstructured":"Tang, C. M. et al. CircRNA_000203 enhances the expression of fibrosis-associated genes by derepressing targets of miR-26b-5p, Col1a2 and CTGF, in cardiac fibroblasts. Sci Rep. 7, 40342 (2017).","journal-title":"Sci Rep."},{"key":"56617_CR27","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.bbrc.2017.04.044","volume":"487","author":"B Zhou","year":"2017","unstructured":"Zhou, B. & Yu, J. W. A novel identified circular RNA, circRNA_010567, promotes myocardial fibrosis via suppressing miR-141 by targeting TGF-beta1. Biochem Biophys Res Commun. 487, 769\u2013775 (2017).","journal-title":"Biochem Biophys Res Commun."},{"key":"56617_CR28","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1016\/j.yjmcc.2017.06.015","volume":"109","author":"D Siede","year":"2017","unstructured":"Siede, D. et al. Identification of circular RNAs with host gene-independent expression in human model systems for cardiac differentiation and disease. J Mol Cell Cardiol. 109, 48\u201356 (2017).","journal-title":"J Mol Cell Cardiol."},{"key":"56617_CR29","first-page":"23","volume":"3","author":"L Monserrat","year":"2018","unstructured":"Monserrat, L. Perspectives on current recommendations for genetic testing in HCM. Glob. Cardiol. Sci. Pract. 3, 23 (2018).","journal-title":"Glob. Cardiol. Sci. Pract."},{"issue":"3","key":"56617_CR30","doi-asserted-by":"publisher","first-page":"1837","DOI":"10.1016\/j.ijcard.2012.12.074","volume":"168","author":"C Bauters","year":"2013","unstructured":"Bauters, C. et al. Circulating miR-133a and miR-423-5p fail as biomarkers for left ventricular remodeling after myocardial infarction. Int.J.Cardiol. 168(3), 1837\u20131840 (2013).","journal-title":"Int.J.Cardiol."},{"key":"56617_CR31","doi-asserted-by":"publisher","first-page":"11227","DOI":"10.1038\/s41598-018-29072-8","volume":"8","author":"S Chatterjee","year":"2018","unstructured":"Chatterjee, S. et al. Leukocyte telomere length correlates with hypertrophic cardiomyopathy severity. Sci Rep. 8, 11227\u2013018-29072-8 (2018).","journal-title":"Sci Rep."},{"key":"56617_CR32","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/s41598-017-00070-6","volume":"7","author":"D de Gonzalo-Calvo","year":"2017","unstructured":"de Gonzalo-Calvo, D. et al. Serum microRNA-1 and microRNA-133a levels reflect myocardial steatosis in uncomplicated type 2 diabetes. Sci Rep. 7, 47\u2013017-00070-6 (2017).","journal-title":"Sci Rep."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-56617-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-56617-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-56617-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,17]],"date-time":"2022-12-17T13:15:43Z","timestamp":1671282943000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-019-56617-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12,30]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2019,12]]}},"alternative-id":["56617"],"URL":"https:\/\/doi.org\/10.1038\/s41598-019-56617-2","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,12,30]]},"assertion":[{"value":"4 October 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 December 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"T.T. has filed patents in the field of non-coding RNAs and is founder and holds shares of Cardior Pharmaceuticals GmbH. D.d.G.C. have licensed a patent on microRNAs as biomarkers. Other authors have no conflicts of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"20350"}}